Afuco™ Anti-MS4A1 ADCC Therapeutic Antibody (Rituximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD20. Rituximab (trade names rituximab and rituximab) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells (this should not be confused with pancreatic β- or beta cells). Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-016 |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | MS4A1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |